Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-100 followed by Pembrolizumab in Malignant Mesothelioma
NCT03644550Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2018
- Primary completion
- Aug 2020
- Modality
- Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of LMB-100 in malignant mesothelioma, sponsored by National Cancer Institute. Started Dec 2018; status: terminated.
02
Drugs
LMB-100
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT03644550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03644550.